PAF announces expansion of Colorectal Care Line

NewsGuard 100/100 Score

The Patient Advocate Foundation (PAF) – a national non-profit resolving patient access to health care issues, medical financial limitations, insurance denials and multiple government program enrollments, including Medicaid and Social Security Disability Income – announced today a significant expansion of its Colorectal Care Line (CCL), beginning September 13, 2010. According to PAF's 2009 Patient Data and Analysis Report (PDAR), colorectal cancer accounted for nearly 25 percent of the cancer diagnosis groups handled by the Foundation last year. The CCL expansion will assist the growing numbers of colorectal cancer patients contacting PAF for access to care support, debt relief and financial assistance – and through the new CCL expansion, PAF will be able to serve an additional 7,200 colorectal patients each year.

"As colorectal cancer is now the third most commonly diagnosed cancer in the United States, with the American Cancer Society estimating nearly 150,000 new cases to be diagnosed this year, it is of utmost importance to PAF to maintain and expand upon our capabilities in helping colon cancer patients who are in need," said Nancy Davenport-Ennis, Founder and CEO of PAF. "We are extremely grateful to our generous program supporters in collaborating on this important CCL expansion, which will help us continue to provide all patients with complete medical, financial and emotional support as they battle against colon cancer."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tumor microbiomes offer new insights for enhancing cancer therapies